Evidence map›Paper›PMID 40384186›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Formation of a β-Endorphin Corona Mitigates Alzheimer's Amyloidogenesis.

Yunxiang Sun, Nicholas Andrikopoulos, Guofang Zhang, Yuying Liu, Xiufang Liang, Dongjie Li, Xiaoman Suo, Yue Wang, Yuhuan Li, Chuang Wang and 3 more

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Formation of a β-Endorphin Corona Mitigates Alzheimer's Amyloidogenesis.Small (Weinheim an der Bergstrasse, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yunxiang SunSchool of Physical Science and Technology, Ningbo University, Ningbo, 315211, China.
Nicholas AndrikopoulosDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Guofang ZhangLaboratory of Immunology and Nanomedicine & China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Laboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Yuying LiuSchool of Physical Science and Technology, Ningbo University, Ningbo, 315211, China.
Xiufang LiangSchool of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 510006, China.
Dongjie LiLaboratory of Immunology and Nanomedicine & China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Laboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Xiaoman SuoLaboratory of Immunology and Nanomedicine & China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Laboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Yue WangSchool of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou, 510006, China.
Yuhuan LiDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Chuang WangSchool of Medicine, Ningbo University, Ningbo, 315211, China.
Yang LiLaboratory of Immunology and Nanomedicine & China-Italy Joint Laboratory of Pharmacobiotechnology for Medical Immunomodulation, Laboratory of Inflammation and Vaccines, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China.
Pu Chun KeDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.
Feng DingDepartment of Physics and Astronomy, Clemson University, Clemson, SC, 29634, USA.ORCID 0000-0003-1850-6336

Funding

Tissue Structural and Neural Remodeling in Human Sacroiliac JointP20GM121342 · NIGMS · CLEMSON UNIVERSITY · PI Jeryl Jones · 2018 to 2026
$24.7M
Inhibition of Human Islet Amyloid Polypeptide AggregationR35GM145409 · NIGMS · CLEMSON UNIVERSITY · PI Feng Ding · 2022 to 2026
$2.0M
Fundamental Research Funds for the Provincial Universities of Zhejiang 172644KYSB20210011Ministry of Science and Technology of China 2021YFA1200900Ministry of Science and Technology of China 2022YFC2409700Ministry of Science and Technology of China 2024YFE0104500National Key Research and Development ProgramNational Outstanding Youth Science Fund Project of National Natural Science Foundation of China 11904189National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 32171390National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 32201154National Outstanding Youth Science Fund Project of National Natural Science Foundation of China 82261138630Natural Science Foundation of Guangdong Province 2023A0505050123Natural Science Foundation of Guangdong Province 2023B1515020104Natural Science Foundation of Guangdong Province 2024A1515011244Natural Science Foundation of Ningbo Municipality 2023J078NIGMS NIH HHS P20 GM121342NIGMS NIH HHS P20GM121342NIGMS NIH HHS R35 GM145409NIGMS NIH HHS R35GM145409Shanghai Magnolia Talent Plan Pujiang Project 24PJA015
6 · The paper itself

Abstract

Senile plaques, comprised of nanosized aggregates of amyloid-β (Aβ) peptides in the brain, are a pathological hallmark of Alzheimer's disease (AD). On the other hand, regular physical exercise is known to significantly reduce the risk of developing AD. Here, it is reported on the transformation and toxicity mitigation of Aβ amyloid aggregation by a spontaneous "corona" of β-endorphin, a major peptide hormone released upon exercise to suppress post-exercise pain. Given that both Aβ and β-endorphin co-localize extracellularly in the brain, it is postulated that β-endorphin may mitigate the toxicity of Aβ aggregation via direct molecular interactions, thereby contributing to an exercise-mediated reduction of AD risk. Combining biophysical characterizations in vitro with atomistic discrete molecular dynamics simulations in silico, a strong interaction is shown between β-endorphin and Aβ, where β-endorphins are located at the periphery to render a corona of their hetero-complexes with Aβ. Cell viability, immunofluorescence and western blotting assays further revealed that the corona shielded cellular exposure to Aβ aggregates and suppressed the toxicity of Aβ in vivo. This work offered a new molecular mechanism for the benefits of physical exercise, which may facilitate a rational design of future therapy and prevention strategies against AD and dementia.

Indexed as

Alzheimer DiseaseAmyloidbeta-EndorphinAmyloid beta-PeptidesAnimalsCell SurvivalHumansMolecular Dynamics SimulationAmyloidAmyloid beta-Peptidesbeta-EndorphinAlzheimer's diseaseAβ aggregationcoronadiscrete molecular dynamicsβ‐endorphin

Identifiers

PMID40384186
PMCPMC12232254

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.